#Netherlands #Utrecht #ViCentra #Kaleido #Reman McDonagh

ViCentra Expands Leadership for Future Growth

ViCentra, the innovative European medical device company, has recently elevated its leadership team with the appointment of Reman McDonagh, PhD, as the new Vice President of Global Marketing. This strategic move is aimed at enhancing the company’s commercial execution in Europe and gearing up for the forthcoming launches of their next-generation Kaleido insulin patch pump system.

Reman McDonagh joins ViCentra with a robust background in diabetes and medical device commercialization, accumulating over two decades of invaluable global experience. Her career trajectory includes impactful roles at prominent organizations such as Roche, Medtronic, Cellnovo, and Insulet, where she adeptly managed brand strategies, market development, and numerous product launches.

The timing of McDonagh's addition to ViCentra coincides with a crucial phase for the company—transitioning from an initial phase of strong traction to a stable, scalable growth model. "Reman is joining us at a pivotal moment in our journey as we are focusing on expanding our presence in key European markets and laying the groundwork for our U.S. market entry," stated Tom Arnold, CEO of ViCentra. Her rare mix of deep subject matter expertise and operational excellence will be instrumental as the company moves forward.

Previously, McDonagh spearheaded the launch of Insulet’s Omnipod DASH across twelve European countries and played a significant role in developing Insulet's European launch strategy for the Omnipod 5 system. As the head of global marketing at ViCentra, she is poised to define the marketing strategy that will bolster the Kaleido system’s unique value proposition and accelerate demand generation in critical markets.

"Kaleido represents a leap forward in insulin delivery systems, crafted with an emphasis on user experience and lifestyle integration," said McDonagh upon her appointment. She expressed her enthusiasm for joining a team determined to enhance market access for patients living with diabetes, emphasizing the importance of providing not only functionality but also the freedom and flexibility needed in daily life.

McDonagh holds a PhD in Chemistry and has a track record of leading international teams focused on commercial strategy and market development, overseeing revenue streams exceeding $400 million annually.

The decision to bring her on board reflects ViCentra’s commitment to building a premier team capable of achieving its long-term growth aspirations while making a substantial difference in the lives of individuals managing diabetes.

About ViCentra

ViCentra is dedicated to revolutionizing the management of diabetes through innovative design and user-friendly solutions. The company is headquartered in Utrecht, Netherlands, and continues to expand its operations across Europe. The Kaleido insulin patch pump system, designed to be a discreet and flexible alternative to traditional insulin pumps, is central to their mission of enhancing patient life. ViCentra boasts a wide array of investors, including Innovation Industries and EQT Life Sciences among others.

About Kaleido

Kaleido stands out as the first insulin patch pump tailored for a modern lifestyle, blurring the line between medical device and personal technology. With its lightweight and compact design, users are empowered to wear the pump in a manner that integrates seamlessly into their lives, facilitating better diabetes management and personal expression. Notably, the Kaleido system leverages advanced algorithms for automated insulin delivery, ensuring precision in therapy while providing the flexibility patients need to navigate their daily routines.